WuXi AppTec Co., Ltd. (WUXIF) は上場企業です ヘルスケア セクターの Medical - Diagnostics & Research 業界で事業展開. 本社所在地は Shanghai, 中国. 現CEOは Ge Li.
WUXIF を有する IPO日 2020-03-17, 39,414 名の正社員, に上場 Other OTC, 時価総額 $41.41B.
WuXi AppTec Co., Ltd. is a leading contract research, development, and manufacturing organization headquartered in Shanghai, China. The company provides comprehensive services across the drug development lifecycle, including discovery, preclinical testing, clinical trials, and commercial manufacturing for small molecule drugs, biologics, and cell and gene therapies. Operating through six business segments—WuXi Chemistry, WuXi Testing, WuXi Biology, WuXi ATU, WuXi DDSU, and others—the company serves pharmaceutical and biotech customers globally across China, Asia, the United States, Europe, and international markets. Founded in 2000, WuXi AppTec has established itself as an integrated solution provider that supports clients from early-stage drug discovery through commercialization across multiple therapeutic modalities.
